What is the Historical Analysis of the Glycomic Therapeutics Market Size?
The glycomic therapeutics market has seen considerable growth due to a variety of factors.
•The market size for glycomic therapeutics has experienced quick expansion in the past few years. Its growth is projected to surge from $164.71 billion in 2024 to $190.03 billion in 2025, with a compound annual growth rate (CAGR) of 15.4%.
The historic period's growth can be linked to a heightened understanding of the importance of glycans, a rise in chronic illnesses, the development of drugs for rare diseases, and collaborative efforts in the field of glycomics research.
What is the Forecasted Growth of the Glycomic Therapeutics Market Size?
The glycomic therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of glycomic therapeutics is anticipated to grow rapidly in the coming years, scaling up to $361.09 billion by 2029 with a compound annual growth rate (CAGR) of 17.4%.
Factors contributing to this projected growth in the forecast period have been identified as the increased understanding of glycan biology, approaches to precision medicine, budding interest in immunotherapy, augmented funding for research on rare diseases, and the emergence of glycan biomarkers. Other notable upcoming trends include the expansion of glycomic applications in the field of oncology, glycoengineering aimed at improved therapeutic proteins, the integration of glycomics in immuno-oncology research, exploration of glycomics in rare and genetic disorders, and regulatory aspects of glycomic drugs.
What Key Factors and Trends are Driving the Growth of the Glycomic Therapeutics Market?
The escalating incidence of diabetes is anticipated to fuel the expansion of the glycomic therapeutics market. Diabetes, a persistent health issue that hampers the body's capacity to control blood sugar (glucose) levels, has been linked to variations in glycans. These variations can contribute to insulin resistance and other metabolic disorders. Distinct glycan patterns are used as biomarkers for the diagnosis of diabetes, the prediction of its progression, and the monitoring of treatment effectiveness. For example, the IDF Diabetes Atlas, a Belgium-based worldwide resource that offers in-depth data and insights on diabetes prevalence, projected in March 2022 that the worldwide prevalence of diabetes will rise from 643 million in 2030 to 783 million by 2045, marking an addition of 140 million cases. Thus, the escalating incidence of diabetes is propelling the expansion of the glycomic therapeutics market.
What are the Market Segments in the Glycomic Therapeutics Market?
The glycomic therapeutics market covered in this report is segmented –
1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications
Subsegments:
1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins
2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides
Pre-Book The Glycomic Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Glycomic Therapeutics Market?
The trend of product innovation is picking up traction in the glycomic therapeutics market. The key players in this sector are directing their efforts towards the creation of new, technologically-advanced, and novel solutions to solidify their market standing. As a case in point, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based out of India, in the recent month of April 2022, commenced the distribution of an innovative fixed-dose combination (FDC) of Teneligliptin, a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), paired with Pioglitazone. This measure aims at enhancing glycemic control and cutting down insulin resistance in individuals suffering from type-2 diabetes.
Who Are the Key Players in the Glycomic Therapeutics Market?
Major companies operating in the glycomic therapeutics market include:
• F Hoffmann-La Roche Ltd.
• Bayer AG
• Sanofi SA
• Thermo Fisher Scientific Inc.
• GlaxoSmithKline plc
• Merck KGaA
• ICON plc
• Agilent Technologies Inc.
• AMS Bio
• Shimadzu Corporation
• Waters Corporation
• Bruker Corporation
• BioMarin Pharmaceutical Inc.
• Bio Techne Corp.
• Promega Corporation
• Halozyme Therapeutics Inc.
• Takara Bio Inc.
• Vector Laboratories
• New England Biolabs Inc.
• Protalix Biotherapeutics Inc.
• Genovis AB
• Ray Biotech Life Inc.
• IEC Group
• Ludger Ltd
• Z Biotech LLC
• Alzheon Inc.
• GlycoMar Limited
What are the Regional Insights into the Glycomic Therapeutics Market?
North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
